Susan Boland
Nurse Practitioner · Austell, GANPI 1588653091
Payments from drug & device makers
Across 230 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$670
- GSK$318
- AstraZeneca$285
- Lilly USA, LLC$278
- AbbVie$269
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$197
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,152100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $670 |
| GSK | 14 | $318 |
| AstraZeneca | 13 | $285 |
| Lilly USA, LLC | 17 | $278 |
| AbbVie | 18 | $269 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $197 |
| Phathom Pharmaceuticals, Inc. | 10 | $172 |
| Merck | 8 | $150 |
| Boehringer Ingelheim | 9 | $148 |
| Pfizer | 9 | $146 |
| Shield Therapeutics Inc | 7 | $130 |
| Sanofi-aventis U.S. LLC | 5 | $126 |
| Abbott | 6 | $123 |
| Astellas Pharma US Inc | 5 | $105 |
| Lundbeck LLC | 4 | $99 |
| Theratechnologies Inc. | 3 | $95 |
| Amgen(2 entities) | 5 | $79 |
| Dexcom, Inc. | 4 | $75 |
| Bayer | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Sumitomo Pharma America, Inc. | 4 | $63 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Sanofi Pasteur Inc. | 2 | $47 |
| Exact Sciences | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 3 | $40 |
| Medtronic | 2 | $39 |
| Novartis | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Biogen | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Dynavax Technologies Corporation | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,152 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $200,631 |
| JardianceEmpagliflozin | 148 | $165,700 |
| EliquisApixaban | 148 | $157,029 |
| FarxigaDapagliflozin Propanediol | 159 | $153,439 |
| JanuviaSitagliptin Phosphate | 90 | $100,661 |
| MounjaroTirzepatide | 85 | $98,946 |
| LinzessLinaclotide | 79 | $58,364 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $40,646 |
| MyrbetriqMirabegron | 34 | $26,602 |
| TrulicityDulaglutide | 23 | $24,610 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $20,834 |
| VascepaIcosapent Ethyl | 38 | $19,266 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 138 | $16,986 |
| XareltoRivaroxaban | 14 | $16,696 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $14,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $670 | $200,631178 claims |
| Boehringer IngelheimJardiance | $148 | $165,700148 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $285 | $164,914178 claims |
| PfizerEliquis | $146 | $157,029148 claims |
| Lilly USA, LLCMounjaro, Trulicity | $278 | $123,556108 claims |
| MerckJanuvia | $150 | $100,66190 claims |
| AbbVieLinzess | $269 | $58,36479 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $318 | $57,85996 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $26,60234 claims |
| Sanofi-aventis U.S. LLCLantus | $126 | $5,14836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Austell
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.